FDA Approves Breakthrough Therapy for Rare Blood Cancer

2026-08-29 companies

Newark, Saturday, 29 August 2026.
The FDA approved MIMRYLO for polycythemia vera after trial data showed 76.9% of patients achieved blood cell control, triggering a $275 million milestone payment to developer Protagonist Therapeutics.

FDA Approval and Drug Mechanism

On August 28, 2026, the U.S. Food and Drug Administration (FDA) approved MIMRYLO (rusfertide), a novel hepcidin mimetic peptide therapy, for the treatment of erythrocytosis in adults with polycythemia vera (PV) [1][2]. This regulatory clearance marks a significant milestone for Protagonist Therapeutics (NASDAQ: PTGX) and its commercialization partner, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) [1][4]. MIMRYLO is administered via once-weekly subcutaneous injection and functions by mimicking the body’s natural hepcidin to regulate iron distribution and red blood cell production [2][5]. The approval establishes MIMRYLO as the first and only hepcidin mimetic peptide therapy available for this indication, offering a new mechanism to maintain hematocrit control [1][3].

Clinical Trial Performance and Patient Impact

The FDA’s decision was supported by results from the Phase 3 VERIFY trial, which demonstrated that 76.9% of patients achieved a clinical response during weeks 20-32 of treatment [1][2]. The study enrolled 293 patients with polycythemia vera, and the primary endpoint was defined as the absence of phlebotomy eligibility, specifically hematocrit levels ≥45% that are ≥3% higher than baseline, or hematocrit ≥48% [2][5]. Maintaining hematocrit levels below 45% is the primary treatment goal to mitigate risks of thrombotic events such as stroke, deep vein thrombosis, and pulmonary embolism [2][4]. Uncontrolled hematocrit is associated with a four-fold increase in cardiovascular death risk, making this control critical for patient survival [2].

Financial Milestones and Commercial Structure

The regulatory clearance triggered a $275 million milestone payment to Protagonist Therapeutics, comprised of a $200 million opt-out fee and a $75 million approval milestone [1]. In addition to the upfront payment, Protagonist is entitled to tiered royalties ranging from 14% to 29% on net sales [1]. The agreement also includes potential for an additional $875 million in future commercial milestones, representing a total potential value of 1150 million based on the initial and future milestones disclosed [1]. This financial structure underscores the commercial value placed on the asset by Takeda following the opt-out election [1][5].

Strategic Outlook and Investor Communications

This marks Protagonist Therapeutics’ second FDA approval in 2026, following the launch of ICOTYDE (icotrokinra) in the U.S. in March 2026 for moderate-to-severe plaque psoriasis [1]. Company leadership described the approval as a paradigm-shifting approach to the management of PV, reflecting years of disciplined investment in innovative projects [1]. Takeda’s Chief Executive Officer Julie Kim noted that the company is at an important inflection point as it prepares to deliver three new medicines with the potential to drive future growth [2]. The development does not impact Takeda’s guidance for the current fiscal year, maintaining stability in their financial outlook [4].

Sources

Biotechnology FDA Approval